1. Search Result
Search Result
Results for "

nsp14

" in MedChemExpress (MCE) Product Catalog:

21

Inhibitors & Agonists

1

Recombinant Proteins

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-149321

    SARS-CoV Infection
    SARS-CoV-2 nsp14-IN-3 (4975) is an inhibitor of the SARS-CoV-2 Nsp14 N7-Methyltransferase (IC50: 3.5 μM) .
    SARS-CoV-2 nsp14-IN-3
  • HY-150680

    SARS-CoV Histone Methyltransferase DNA Methyltransferase Infection
    SARS-CoV-2 nsp14-IN-1 (Compound 3) is a prototypic bisubstrate inhibitor of SARS-CoV-2 Nsp14 MTase with an IC50 value of 0.061 μM. SARS-CoV-2 nsp14-IN-1 (Compound 3) has an excellent selectivity profile over a panel of human methyltransferases, can against apanel of 10 human MTases including histone lysine, proteinarginine, and DNA and RNA MTases .
    SARS-CoV-2 nsp14-IN-1
  • HY-150681

    SARS-CoV Infection
    SARS-CoV-2 nsp14-IN-2 is a potent SARS-CoV-2 Nsp14 methyltransferase inhibitor with an IC50 value of 0.093 µM. SARS-CoV-2 nsp14-IN-2 shows antiviral activity. SARS-CoV-2 nsp14-IN-2 shows plasma and liver S9 stability. SARS-CoV-2 nsp14-IN-2 has the potential for the research of COVID-19 .
    SARS-CoV-2 nsp14-IN-2
  • HY-155679

    SARS-CoV Infection
    SARS-CoV-2 nsp14-IN-4 (Compound 12q) is an inhibitor of SARS-CoV-2 nsp14 methyltransferase (IC50=19 nM). SARS-CoV-2 nsp14-IN-4 is non-cytotoxic and cell-permeable. SARS-CoV-2 nsp14-IN-4 is used in COVID-19 research .
    SARS-CoV-2 nsp14-IN-4
  • HY-153719

    SARS-CoV Infection
    NSC111552 is a potent SARS-CoV-2 NSP14 MTase inhibitor. NSC111552 inhibits the FL-NAH binding to the SARS-CoV-2 NSP14 MTase with an IC50 of 5.1 μM .
    NSC111552
  • HY-149317

    SARS-CoV Infection
    ZINC475239213 is an inhibitor of the SARS-CoV-2 Nsp14 N7-Methyltransferase (IC50: 20 μM) .
    ZINC475239213
  • HY-149319

    SARS-CoV Infection
    ZINC61142882 is an inhibitor of the SARS-CoV-2 Nsp14 N7-Methyltransferase (IC50: 6 μM) .
    ZINC61142882
  • HY-149322

    SARS-CoV Infection
    Z795161988 is an inhibitor of the SARS-CoV-2 Nsp14 N7-Methyltransferase (IC50: 2.2 μM) .
    Z795161988
  • HY-163614

    SARS-CoV DNA Methyltransferase Infection
    SARS-CoV-2-IN-87 (compound 138968421) is a potent inhibitor of methyltransferases (nsp14 and nsp16) of SARS-CoV-2 .
    SARS-CoV-2-IN-87
  • HY-149320

    SARS-CoV Infection
    Acryl42-10 is a covalent inhibitor of the SARS-CoV-2 Nsp14 N7-Methyltransferase (IC50: 7 μM) .
    Acryl42-10
  • HY-155983

    SARS-CoV Infection
    SARS-CoV-2 nsp14-IN-4 (Compound 12q) is a selective SARS-CoV-2 nsp14 methyltransferase inhibitor with an IC50 value of 19 ± 2.5 nM. SARS-CoV-2 nsp14-IN-4 (Compound 12q) do not have a zwitterionic character and can penetrate into cells. SARS-CoV-2 nsp14-IN-4 (Compound 12q) can be used for COVID-19 and its causative agent SARS-CoV-2 research .
    E07 aptamer
  • HY-143467

    SARS-CoV Infection
    SARS-CoV-IN-4 (compound 13) is a potent and specific inhibitor of SARS-CoV nsp14 N7-methyltransferase, with an IC50 of 0.6 μM (SARS-CoV nsp14) .
    SARS-CoV-IN-4
  • HY-162177

    SARS-CoV Infection
    SARS-CoV-2-IN-78 (compound 3) is an inhibitor for nsp14 of SARS-Cov-2. SARS-CoV-2-IN-78 reveals antiviral activity as N7 methyltrabsferase .
    SARS-CoV-2-IN-78
  • HY-124654

    SARS-CoV Metabolic Disease
    SS148 is a dual inhibitor of nsp14/nsp16 MTase. SS148 significant inhibits nsp10–nsp16 with an IC50 of 1.2 μM .
    SS148
  • HY-W423489

    S-Adenosyl-DL-homocysteine

    SARS-CoV Infection
    SARS-CoV-2-IN-76 (compound 1) is a nsp14-viral cap N7 methyltranferase and PLpro inhibitor of severe acute respiratory syndrome corona virus (SARS-CoV-2) .
    SARS-CoV-2-IN-76
  • HY-168441

    SARS-CoV Infection
    NCGC00537446 is a dual Nsp14 MTase/ExoN inhibitor. NCGC00537446 can be used for the research of SARS-CoV-2 replication and infection .
    NCGC00537446
  • HY-149362

    SARS-CoV Infection
    MTase-IN-1 (compound 26) is a potent and selective inhibitor of coronavirus nsp14 N7-methyltransferases, with an IC50 of 0.72 nM. MTase-IN-1 impairs viral RNA translation and immune evasion .
    MTase-IN-1
  • HY-W024485

    SARS-CoV Infection
    SARS-CoV-2-IN-86 (Compound 2734589) is a dual inhibitor of the methyltransferases nsp14 and nsp16 of SARS-CoV-2. SARS-CoV-2-IN-86 exhibits low toxicity with a LD50 of 700 mg/kg according to toxicity analysis predict .
    SARS-CoV-2-IN-86
  • HY-170523

    SARS-CoV DNA Methyltransferase Infection
    RU-0415529 is an orally active inhibitor for SARS-CoV-2 nonstructural protein 14 (NSP14) with an IC50 of 356 nM. RU-0415529 binds to the SAH-stabilized cap binding pocket, inhibits viral RNA methylation and the viral replication. RU-0415529 exhibits anti-infectious activity in mouse models .
    RU-0415529
  • HY-159890

    SARS-CoV Infection
    MTI013 is a selective SARS-CoV-2 nsp14 Mtase inhibitor (IC50: 2.98 μM) and an antiviral agent (IC50: 10.33 μM in HCoV-229E-infected Huh7 cells). MTI013 also shows a synergistic antiviral effect with the RdRp inhibitor SHEN26 (HY-155488) .
    MTI013
  • HY-170524

    SARS-CoV DNA Methyltransferase Infection
    TDI-015051 is an orally active inhibitor for SARS-CoV-2 nonstructural protein 14 (NSP14) with an IC50 ≤0.15 nM. TDI-015051 inhibits SARS-CoV-2 NSP14 in Huh-7.5 cell (EC50=11.4 nM) and in ACE2-TMPRSS2 expressing A549 cell (EC50=64.7 nM). TDI-015051 also inhibits other coronaviruses like α-hCoV-NL63, α-hCoV-229E and β-hCoV-MERS with IC50s of 1.7, 2.6 and 3.6 nM, respectively. TDI-015051 binds to the SAH-stabilized cap binding pocket, inhibits viral RNA methylation and viral replication, and exhibits anti-infectious activity in mouse models .
    TDI-015051